How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?

  • Question on Document

    We would like to draw your attention to the new minimum evidence standards section (section 5). Please consider it and comment on whether it reflects sufficient criteria for future NICE recommendations of digital technologies for supporting self-management of COPD.

  • Question on Document

    Are there any implementation considerations for digital technologies for supporting self-management of COPD that we may have missed?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Evidence generation plan

Closed for comments This consultation ended on at   Request commenting lead permission

5 Minimum evidence standards

All the technologies that have been recommended for use in the NHS while more evidence is generated have some clinical evidence suggesting that they may improve symptoms of COPD, enhance respiratory function, and reduce exacerbations. None of the technologies reported any safety concerns when using the digital technologies to support self-management of COPD.

In addition to the evidence above, the committee has indicated that it may be able to recommend technologies in this topic area in the future that have evidence for:

  • a beneficial impact of the digital technologies compared with standard self-management of COPD without digital technologies

  • long-term clinical improvement in COPD using COPD Assessment Test (CAT) score and the number of exacerbations

  • resource use associated with the technologies and NHS standard care

  • intervention acceptance, completion rates, patient preference, and uptake rates

  • adverse events.

Companies can strengthen the evidence base by also having evidence for:

  • effects on health-related quality of life measured through the EQ-5D

  • effectiveness in different subgroups

  • where the technologies are used in the care pathway.